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Role of Assay Type in Determining Free 25-Hydroxyvitamin D 
Levels in Diverse Populations
To the Editor: It is unclear whether circulating 
free or bioavailable 25-hydroxyvitamin D is a 
better marker of vitamin D status than is total 
25-hydroxyvitamin D, especially in racially di-
verse populations. Until recently, the only meth-
od to compare the levels was to estimate the 
level of free or bioavailable 25-hydroxyvitamin D 
from total 25-hydroxyvitamin D, vitamin D–
binding protein (also known as gc-globulin, 
encoded by the GC gene), and albumin, with or 
without the GC genotype. Powe et al. reported 
that levels of vitamin D–binding protein, as 
measured on a monoclonal enzyme-linked im-
munosorbent assay (ELISA, R&D Systems), were 
lower in black participants than in white par-
ticipants in the United States.1 Consequently, 
calculated levels of bioavailable 25-hydroxyvita-
min D were shown to be similar in black par-
ticipants and white participants, despite a lower 
mean level of total 25-hydroxyvitamin D in black 
participants.2 This finding gained widespread 
attention and was suggested to have implica-
tions for screening for 25-hydroxyvitamin D and 
for health policy.3
Here we present evidence that the use of a 
monoclonal ELISA to measure vitamin D–bind-
ing protein in persons of African ancestry intro-
duces a critical flaw into the calculation of free 
or bioavailable 25-hydroxyvitamin D,4 a limitation 
that influenced the conclusions of Powe et al. and 
other investigators. In addition, we present racial 
and geographic comparisons of directly mea-
sured free 25-hydroxyvitamin D.
In two studies involving a total of 1057 black 
men and non-Hispanic white men in the United 
States (the Osteoporotic Fractures in Men study) 
and in the United Kingdom and Gambia (the 
Medical Research Council study), we compared 
circulating levels of total 25-hydroxyvitamin D 
on liquid chromatography–tandem mass spec-
trometry with directly measured free 25-hydroxy-
vitamin D (ELISA, Future Diagnostics) and calcu-
lated levels of free 25-hydroxyvitamin D, using 
levels of 25-hydroxyvitamin D and vitamin D–
binding protein as measured by means of mono-
clonal ELISA, polyclonal radial immunodiffu-
sion, and two polyclonal ELISAs (Table 1).
The median level of vitamin D–binding pro-
tein on monoclonal ELISA in men of African 
ancestry was approximately 65% lower than the 
level in white men, whereas the level of vitamin 
D–binding protein was nearly identical in all 
groups when measured by means of polyclonal 
antibodies against vitamin D–binding protein. 
The fact that levels of vitamin D–binding protein 
do not vary between races was confirmed by mea-
surements of two nonvariant and five GC-variant 
peptides of vitamin D–binding protein by means 
of proteomic methods (data not shown), which 
support the findings of recent mass spectrome-
try studies.5 Racial and geographic differences 
in levels of total 25-hydroxyvitamin D were re-
flected in directly measured levels of free 
25-hydroxy vitamin D, with lower levels in black 
men than in white men in the United States 
(Table 1).
Levels of free and total 25-hydroxyvitamin D 
were strongly correlated (overall Spearman’s cor-
relation coefficient, 0.84). Similarly, levels of 
total 25-hydroxyvitamin D were highly correlat-
ed with calculated levels of free 25-hydroxyvita-
min D derived from the two polyclonal measures 
of vitamin D–binding protein (r≥0.93) but not 
from the monoclonal assay (r = 0.54). Levels of 
measured free 25-hydroxyvitamin D and levels 
that were calculated on the basis of polyclonal 
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antibodies against vitamin D–binding protein 
were strongly correlated (r≥0.80), whereas mea-
sured levels and levels that were calculated on 
the basis of monoclonal antibodies against vita-
min D–binding protein were only moderately 
correlated (r = 0.56).
In conclusion, median levels of free 25-hydroxy-
vitamin D were significantly lower in black men 
than in white men in the United States when the 
levels were measured directly or calculated on 
the basis of polyclonal antibodies against vitamin 
D–binding protein. However, both measured and 
calculated median levels of free 25-hydroxy-
vitamin D were lower in white men in the United 
Kingdom than in black men in Gambia. These 
findings are consistent with the median levels of 
total 25-hydroxyvitamin D in all the study par-
ticipants. These results contradict previous re-
ports of similar levels of free or bioavailable 
25-hydroxyvitamin D between races. Our results 
underscore the importance of the choice of assay 
for vitamin D–binding protein in the calculation 
of free 25-hydroxyvitamin D in diverse popula-
tions and support the measurement of total 
25-hydroxyvitamin D in the general population 
as a marker of vitamin D status, regardless of 
race or GC genotype.
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Substance and Type of Assay MrOS Study MRC Study
White Men 
(N = 919)
Black Men 
(N = 101)
White Men  
(N = 18)
Black Men  
(N = 19)
median (interquartile range)
Total 25-hydroxyvitamin D (nmol/liter)† 62.2 (50.4–73.4) 38.4 (24.5–53.9) 25.6 (22.8–36.2) 65.1 (57.1–78.3)
Vitamin D–binding protein (μmol/liter)
Polyclonal radial immunodiffusion 5.11 (4.69–5.48) 5.08 (4.67–5.48) 5.22 (4.79–5.48) 4.79 (4.46–5.31)
Polyclonal ELISA: GenWay‡ 4.79 (4.29–5.31) 5.33 (5.00–5.69) ND ND
Polyclonal ELISA: Immundiagnostik‡ ND ND 6.77 (6.60–7.58) 6.65 (6.10–7.17)
Monoclonal ELISA: R&D Systems† 4.86 (3.94–6.15) 1.77 (1.34–3.25) 5.50 (4.04–6.19) 1.94 (1.64–3.85)
Calculated free 25-hydroxyvitamin D (pmol/liter)§
Polyclonal radial immunodiffusion† 27.2 (22.5–32.5) 17.3 (10.3–23.1) 11.2 (9.4–18.1) 31.4 (24.7–37.7)
Polyclonal ELISA: GenWay† 29.0 (23.3–34.5) 16.8 (9.7–22.1) ND ND
Polyclonal ELISA: Immundiagnostik† ND ND 8.7 (6.7–13.7) 23.8 (20.4–27.9)
Monoclonal ELISA: R&D Systems¶ 28.1 (21.7–35.8) 31.3 (19.8–50.6) 12.0 (8.5–18.7) 56.9 (45.1–69.2)
Directly measured free 25-hydroxyvitamin D: Future 
Diagnostics and DIAsource (pmol/liter)†‖
13.2 (11.0–16.5) 9.0 (7.5–11.5) 7.1 (5.5–8.3) 16.0 (14.1–20.4)
*  The Osteoporotic Fractures in Men (MrOS) study involved men 65 years of age or older in the United States, and the Medical Research 
Council (MRC) study involved men between the ages of 25 and 39 years in the United Kingdom and Gambia. P values for all listed compari-
sons in each study were performed by means of the Wilcoxon rank-sum test. P>0.10 for all comparisons with no P value indicated. To con-
vert the values for total 25-hydroxyvitamin D to nanograms per milliliter, divide by 2.496. ND denotes not done.
†  P<0.001 for the comparisons between the two groups in both studies.
‡  P<0.001 in the MrOS study and P = 0.30 in the MRC study.
§  Findings with respect to free 25-hydroxyvitamin D were similar to those for calculated bioavailable 25-hydroxyvitamin D (r = 0.99).
¶  P = 0.04 in the MrOS study and P<0.001 in the MRC study.
‖  For directly measured free 25-hydroxyvitamin D in the MrOS study, the evaluations were performed in 194 non-Hispanic white men and 80 
black men.
Table 1. Levels of Total and Free 25-Hydroxyvitamin D and Vitamin D–Binding Protein, According to Race and Geographic Region.*
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